Literature DB >> 26786656

Detection of IgG1 antibodies against Mycobacterium tuberculosis DosR and Rpf antigens in tuberculosis patients before and after chemotherapy.

Ana Márcia Menezes Mattos1, Alexandre Silva Chaves1, Kees L M C Franken2, Bárbara Bruna Muniz Figueiredo1, Ana Paula Ferreira1, Tom H M Ottenhoff2, Henrique Couto Teixeira3.   

Abstract

Diagnosis of tuberculosis (TB) remains challenging. Serum IgG1 antibodies against Mycobacterium tuberculosis active growth phase antigens (ESAT-6/CFP-10, Rv0717 and Rv3353), DosR regulon-encoded proteins (Rv1733, Rv1737, Rv2628 and Rv2029), and resuscitation-promoting factors (Rv0867 and Rv2389) were evaluated in TB patients using ELISA. Active TB patients showed elevated levels of IgG1 antibodies against ESAT-6/CFP-10, Rv0717, Rv3353, Rv1733, Rv2628, Rv2029 and Rv0867 in comparison to healthy controls (p < 0.001). These levels remained high after the initiation of treatment, while responses to Rv0717 and Rv1733 peaked early during treatment. IgG1 responses to ESAT-6/CFP-10, Rv3353, Rv2628, Rv2029 and Rv0867 declined to control levels after the completion of 6 months chemotherapy. ROC analysis confirmed the good diagnostic performance of Rv0717, Rv1733, Rv3353, Rv2628, Rv2029 and Rv0867antigens. These data suggest that detecting IgG1 antibodies against M. tuberculosis antigens, including DosR and Rpf proteins, may represent an additional tool in the diagnosis of tuberculosis.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DosR; ESAT-6; IgG1; Rpf antigens; Tuberculosis

Mesh:

Substances:

Year:  2015        PMID: 26786656     DOI: 10.1016/j.tube.2015.11.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

Review 1.  Antibodies and tuberculosis.

Authors:  Ashley J Jacobs; Juthathip Mongkolsapaya; Gavin R Screaton; Helen McShane; Robert J Wilkinson
Journal:  Tuberculosis (Edinb)       Date:  2016-08-26       Impact factor: 3.131

2.  Humoral Responses to Rv1733c, Rv0081, Rv1735c, and Rv1737c DosR Regulon-Encoded Proteins of Mycobacterium tuberculosis in Individuals with Latent Tuberculosis Infection.

Authors:  Simon G Kimuda; Angela Nalwoga; Jonathan Levin; Kees L M C Franken; Tom H M Ottenhoff; Alison M Elliott; Stephen Cose; Irene Andia-Biraro
Journal:  J Immunol Res       Date:  2017-02-01       Impact factor: 4.818

3.  Antibody response against PhoP efficiently discriminates among healthy individuals, tuberculosis patients and their contacts.

Authors:  Aurobind Vidyarthi; Nargis Khan; Tapan Agnihotri; Kaneez F Siddiqui; Girish R Nair; Ashish Arora; Ashok K Janmeja; Javed N Agrewala
Journal:  PLoS One       Date:  2017-03-20       Impact factor: 3.240

Review 4.  An Inflammatory Story: Antibodies in Tuberculosis Comorbidities.

Authors:  Milla R McLean; Lenette L Lu; Stephen J Kent; Amy W Chung
Journal:  Front Immunol       Date:  2019-12-09       Impact factor: 7.561

5.  Antibody Subclass and Glycosylation Shift Following Effective TB Treatment.

Authors:  Patricia S Grace; Sepideh Dolatshahi; Lenette L Lu; Adam Cain; Fabrizio Palmieri; Linda Petrone; Sarah M Fortune; Tom H M Ottenhoff; Douglas A Lauffenburger; Delia Goletti; Simone A Joosten; Galit Alter
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

Review 6.  Immunological Impacts of Diabetes on the Susceptibility of Mycobacterium tuberculosis.

Authors:  Birhanu Ayelign; Markos Negash; Meaza Genetu; Tadelo Wondmagegn; Tewodros Shibabaw
Journal:  J Immunol Res       Date:  2019-09-09       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.